Lannett Company, Inc. (NYSE:LCI) announced that the company will be added to the S&P SmallCap 600 Index, after the close of trading. Lannett Company, Inc. (NYSE:LCI) net profit margin is 13.30% and weekly performance is 10.42%. On last trading day company shares ended up $42.16. Analysts mean target price for the company is $47.25. Lannett Company, Inc. (NYSE:LCI) distance from 50-day simple moving average is 18.05%.
Express Scripts Holding Company (NASDAQ:ESRX)was downgraded by equities researchers at Cowen and Company from an “outperform” rating to a “market perform” rating in a research report issued on Monday. Express Scripts Holding Company (NASDAQ:ESRX) shares fell -2.00% in last trading session and ended the day on $70.04. ESRX Gross Margin is 7.80% and its return on assets is 4.00%. Express Scripts Holding Company (NASDAQ:ESRX) quarterly performance is -5.94%.
Johnson & Johnson, the world’s biggest health-care products maker, and Bausch & Lomb were among firms fined a combined $3 million for price fixing in China’s contact lens and eye-glass market. Johnson & Johnson (NYSE:JNJ) shares moved up 0.70% in last trading session and was closed at $102.17, while trading in range of $101.01-$102.26. Johnson & Johnson (NYSE:JNJ) year to date performance is 13.13%.
Zacks reissued their neutral rating on shares of Boston Scientific (NYSE:BSX) in a research report sent to investors on Friday morning. The firm currently has a $14.00 price target on the stock. Boston Scientific Corporation (NYSE:BSX) ended the last trading day at $12.88. Company weekly volatility is calculated as 1.81% and price to cash ratio as 89.19. Boston Scientific Corporation (NYSE:BSX) showed a positive weekly performance of 0.39%.
Gilead Sciences Canada, Inc. is pleased to announce that the Health and Social Services Ministry has placed Sovaldi® (sofosbuvir), the newest treatment for chronic hepatitis C virus (HCV) infection approved for sale in Canada, on the Liste de médicaments (effective June 2, 2014). With this listing, Quebecbecomes the first Canadian province to provide access to Sovaldi for treatment-naïve patients with genotypes 1 and 4 HCV infection regardless of liver severity. Gilead Sciences, Inc. (NASDAQ:GILD) net profit margin is 33.50% and weekly performance is 0.75%. On last trading day company shares ended up $81.55. Analysts mean target price for the company is $100.57. Gilead Sciences, Inc. (NASDAQ:GILD) distance from 50-day simple moving average is 8.02%.
Leave a Reply